ERAAs for menopause treatment: Welcome the ‘designer estrogens’

2017/01/01 by Heather D. Hirsch, Elim Shih, Holly L. Thacker · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · #Estrogen and related hormone effects #Menopause: Health Impacts and Treatments #Endometriosis Research and Treatment

paper · pdf · doi:10.3949/ccjm.84a.15140

openalex publication_date 2017/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.

Cited by

• Selective estrogen receptor modulator [wikipedia]

Related

• Pharmacology and clinical applications of selective estrogen receptor modulators
• Estrogen Receptors: Therapies Targeted to Receptor Subtypes
• Menopausal hormone therapy: a better and safer future
• European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause
• Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast